TEP/TDM au fluorure (18F) de sodium pour la détection des métastases osseuses du cancer de la prostate. Description de l’étude Fluprostic de comparaison de la TEP/TDM au fluorure (18F) de sodium à l’IRM corps entier dans cette indication

Médecine Nucléaire - Tập 33 - Trang 388-397 - 2009
V. Huchet1, F. Paycha2, S. Balogova1, A. Halimi1, K. Kerrou1, O. Pascal1, F. Montravers1, J.-N. Talbot1
1Services de médecine nucléaire, hôpital Tenon, université Pierre-et-Marie-Curie, AP–HP, 4, rue de Chine, 75020 Paris, France
2Hôpital Louis-Mourier, AP–HP, Colombes, France

Tài liệu tham khảo

Wu, 2006, Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone, Brit J Urol, 99, 525, 10.1111/j.1464-410X.2006.06654.x

Singh, 2004, Is there a favorable subset of patients with prostate cancer who develop oligometastases?, Int J Radiat Oncol Biol Phys, 58, 3, 10.1016/S0360-3016(03)01442-1

Carducci, 2006, Targeting bone metastasis in prostate cancer with endothelin receptor antagonists, Clin Cancer Res, 12, 6296, 10.1158/1078-0432.CCR-06-0929

Tu, 2001, Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial, Lancet, 357, 10.1016/S0140-6736(00)03639-4

Akerley, 2002, A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone, Cancer, 94, 1654, 10.1002/cncr.10437

Lam, 2008, Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases, Eur J Nucl Med Mol Imaging, 35, 756, 10.1007/s00259-007-0659-z

Blau, 1962, A new isotope for bone scanning, J Nucl Med, 3, 332

Paycha F, Richard B. Exploration scintigraphique du squelette. Encycl Méd Chir (Éditions scientifiques et médicales Elsevier SAS, Paris), Radiodiagnostic-Squelette normal, 30-480-A-10, 2001, 37 p.

Toegel, 2006, Uptake of bone-seekers is solely associated with mineralization ! A study with (99m)Tc-MDP, (153)Sm-EDTMP and (18)F-fluoride on osteoblasts, Eur J Nucl Med Mol Imaging, 33, 491, 10.1007/s00259-005-0026-x

Paycha, 2007, Quelle est la signification des anomalies observées en scintigraphie osseuse ? Retour sur les mécanismes de fixation des bisphosphonates-(99mTc), Méd Nucl., 31, 356, 10.1016/j.mednuc.2007.06.008

Hawkins, 1992, Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET, J Nucl Med., 33, 633

Grant, 2008, Skeletal PET with 18F-fluoride: applying new technology to an old tracer, J Nucl Med., 49, 68, 10.2967/jnumed.106.037200

Lim, 2007, Early experience with fluorine-18 sodium fluoride bone PET in young patients with back pain, J Pediatr Orthop, 27, 277, 10.1097/BPO.0b013e31803409ba

Ovadia, 2007, Back pain in adolescents: assessment with integrated 18F-fluoride positron-emission tomography-computed tomography, J Pediatr Orthop., 27, 90, 10.1097/01.bpo.0000242438.11682.10

Taoka, 2001, Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy, AJR Am J Roentgenol., 176, 1525, 10.2214/ajr.176.6.1761525

Even-Sapir, 2006, The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT, J Nucl Med, 47, 287

Paycha, 2005, Métastases osseuses du cancer de la prostate et scintigraphie osseuse, Méd Nucl, 29, 501

Roudier, 2003, Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results, Clin Exp Metastasis, 20, 171, 10.1023/A:1022627421000

Dotan, 2005, Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy, J Clin Oncol, 23, 1962, 10.1200/JCO.2005.06.058

Ishizuka, 2005, Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan, Int J Urol, 12, 728, 10.1111/j.1442-2042.2005.01118.x

Hricak, 2007, Imaging prostate cancer: a multidisciplinary perspective, Radiology, 243, 28, 10.1148/radiol.2431030580

Lin, 1999, The value of a baseline bone scan in patients with newly diagnosed prostate cancer, Clin Nucl Med, 24, 579, 10.1097/00003072-199908000-00007

Römer, 2006, SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients, J Nucl Med., 47, 1102

Alavi, 2008, Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?, Eur J Nucl Med Mol Imaging, 35, 1554, 10.1007/s00259-008-0813-2

Schirrmeister, 1999, Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET, J Nucl Med, 40, 1623

Langsteger, 2006, The role of fluorodeoxyglucose, 18Fdihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast, Semin Nucl Med., 36, 73, 10.1053/j.semnuclmed.2005.09.002

Yeh, 1996, Detection of bony metastases of androgen-independent prostate cancer by PET-FDG, Nucl Med Biol, 23, 693, 10.1016/0969-8051(96)00044-3

Shreve, 1996, Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose, Radiology, 199, 751, 10.1148/radiology.199.3.8638000

Morris, 2002, Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer, Urology, 59, 913, 10.1016/S0090-4295(02)01509-1

Kotzerke, 2003, Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer, Nuklearmedizin, 42, 25, 10.1055/s-0038-1623902

Fricke, 2003, Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients, Eur J Nucl Med Mol Imaging, 30, 607, 10.1007/s00259-002-1104-y

De Jong, 2003, 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer, Eur Urol, 44, 32, 10.1016/S0302-2838(03)00207-0

Eschmann, 2007, Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer, Nuklearmedizin, 46, 161, 10.1160/nukmed-0075

De Grado, 2001, Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer, Cancer Res, 61, 110

Price, 2002, Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron tomography of androgen dependent and androgen independent prostate cancer, J Urol, 168, 273, 10.1016/S0022-5347(05)64906-3

Cimitan, 2006, [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients, Eur J Nucl Med Mol Imaging, 33, 1387, 10.1007/s00259-006-0150-2

Beheshti, 2008, Detection of bone metastases in patients with prostate cancer by F-18 fluorocholine and F-18 fluoride PET-CT: a comparative study, Eur J Nucl Med Mol Imaging, 35, 1766, 10.1007/s00259-008-0788-z

Tombal, 2005, Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases, Prostate., 65, 178, 10.1002/pros.20280

Pomeranz, 1994, Bone scintigraphy and multimodality imaging in bone neoplasia: strategies for imaging in the new health care climate, Semin Nucl Med, 24, 188, 10.1016/S0001-2998(05)80010-8

Freedman, 1999, Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer, Urology., 54, 118, 10.1016/S0090-4295(99)00090-4

Daffner, 1986, MRI in the detection of malignant infiltration of bone marrow, Am J Roentgenol, 146, 353, 10.2214/ajr.146.2.353

Lecouvet, 2007, Magnetic Resonance Imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies, J Clin Oncol, 25, 3281, 10.1200/JCO.2006.09.2940

Venkitaraman, 2007, Outcome of early detection and radiotherapy for occult spinal cord compression, Radiother Oncol., 85, 469, 10.1016/j.radonc.2007.10.043

Venkitaraman, 2009, Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? Clin Oncol (R Coll Radiol)., 21, 39

Castillo, 2000, Diffusion-weighted MR imaging offers no advantage over routine noncontrast MR imaging in the detection of vertebral metastases, AJNR Am J Neuroradiol., 21, 948

Nakanishi, 2007, Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images, Magn Reson Med Sci, 6, 147, 10.2463/mrms.6.147

Ketelsen, 2008, Detection of bone metastasis of prostate cancer – comparison of whole-body MRI and bone scintigraphy, Rofo, 180, 746, 10.1055/s-2008-1027479

Nemeth, 2007, Improved detection of skull metastasis with diffusion-weighted MR imaging, Am J Neuroradiol, 28, 1088, 10.3174/ajnr.A0501

Thông tin
Thông tin xuất bản

Médecine Nucléaire

Tập 33

388-397

Thông tin tác giả